## Ashvini Keshavan

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7680763/publications.pdf

Version: 2024-02-01

62 papers 1,255 citations

<sup>394286</sup>
19
h-index

377752 34 g-index

66 all docs 66
docs citations

66 times ranked 2166 citing authors

#	Article	IF	CITATIONS
1	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	1.8	5
2	CSF biomarkers for dementia. Practical Neurology, 2022, 22, 285-294.	0.5	3
3	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72 </i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
4	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
5	Associations of Î <sup>2</sup> -Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. Neurology, 2022, 99, .	1.5	12
6	Pure tone audiometry and cerebral pathology in healthy older adults. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A9.1-A9.	0.9	0
7	Population-based blood screening for pre-clinical Alzheimer's disease: a British birth cohort at age 70. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A91.2-A91.	0.9	O
8	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12131.	1.2	19
9	A populationâ€based study of head injury, cognitive function and pathological markers. Annals of Clinical and Translational Neurology, 2021, 8, 842-856.	1.7	5
10	Investigating the relationship between BMI across adulthood and late life brain pathologies. Alzheimer's Research and Therapy, 2021, 13, 91.	3.0	7
11	Subjective cognitive complaints at age 70: associations with amyloid and mental health. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1215-1221.	0.9	16
12	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	2.7	54
13	Bilateral optic neuritis as a first presentation of lymph node tuberculosis. Practical Neurology, 2021, , practneurol-2021-003086.	0.5	1
14	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. Brain Communications, 2021, 3, fcab003.	1.5	8
15	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Communications, 2021, 3, fcab099.	1.5	43
16	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54
17	Dissociable effects of APOE $\hat{l}\mu4$ and $\hat{l}^2$ -amyloid pathology on visual working memory. Nature Aging, 2021, 1, 1002-1009.	5 <b>.</b> 3	16
18	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimerâ $\in$ <sup>™</sup> s disease in the UK. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
19	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
20	Fixelâ€based analysis of the effect of amyloid beta on white matter tracts in neurologically normal 70 year olds. Alzheimer's and Dementia, 2021, 17, .	0.4	0
21	Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life. JAMA Neurology, 2020, 77, 175.	4.5	55
22	Increased variability in reaction time is associated with amyloid beta pathology at age 70. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12076.	1.2	8
23	Plasma phosphoâ€tau181 in over 400 cognitively healthy 69†to 71â€yearâ€olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. Alzheimer's and Dementia, 2020, 16, e037848.	0.4	О
24	Vascular risk factors and amyloid pathology: Additive or interactive associations?. Alzheimer's and Dementia, 2020, 16, e037922.	0.4	0
25	Performance on the graded naming test in a populationâ€based sample of 72â€yearâ€olds: Associations with lifeâ€course predictors and βâ€amyloid pathology. Alzheimer's and Dementia, 2020, 16, e040897.	0.4	O
26	Accelerated forgetting is sensitive to βâ€amyloid pathology and cerebral atrophy in cognitively normal 72â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e040987.	0.4	0
27	APOEâ€Îµ4 carriers have superior recall on the †What was where?' visual shortâ€term memory binding test at age 70, despite a detrimental effect of βâ€amyloid. Alzheimer's and Dementia, 2020, 16, e041090.	0.4	4
28	Lifetime cigarette smoking and laterâ€life brain health: The populationâ€based 1946 British Birth Cohort. Alzheimer's and Dementia, 2020, 16, e041111.	0.4	1
29	Cerebral amyloid and white matter hyperintensity volume are independently associated with rates of cerebral atrophy in Insight 46, a subâ€study of the 1946 British birth cohort. Alzheimer's and Dementia, 2020, 16, e044924.	0.4	O
30	Midâ€life blood pressure and microstructural white matter: Findings from the 1946 British birth cohort. Alzheimer's and Dementia, 2020, 16, e045707.	0.4	0
31	Serum neurofilament light and whole brain volume associate with machineâ€learning derived brainâ€predicted age in the British 1946 birth cohort. Alzheimer's and Dementia, 2020, 16, e045965.	0.4	1
32	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
33	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12097.	1.2	5
34	Olfactory testing does not predict $\hat{l}^2$ -amyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort. Journal of Neurology, 2020, 267, 3329-3336.	1.8	4
35	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. Dementia and Geriatric Cognitive Disorders, 2020, 49, 56-76.	0.7	27
36	Pure tone audiometry and cerebral pathology in healthy older adults. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 172-176.	0.9	16

3

#	Article	IF	CITATIONS
37	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	1.2	38
38	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurology, The, 2019, 18, 942-952.	4.9	178
39	Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946. PLoS ONE, 2019, 14, e0224030.	1.1	26
40	Cognition at age 70. Neurology, 2019, 93, e2144-e2156.	1.5	37
41	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	0.9	23
42	P68â€Divergent associations between life course cognitive trajectories and brain pathologies: findings from the 1946 british birth cohort. , 2019, , .		0
43	CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. Alzheimer's Research and Therapy, 2019, 11, 105.	3.0	31
44	O4â $\in$ 13â $\in$ 01: EARLY ADULTHOOD VASCULAR RISK STRONGLY PREDICTS BRAIN VOLUMES AND WHITE MATTER DISEASE, BUT NOT AMYLOID STATUS, AT AGE 69â $\in$ "71 YEARS: EVIDENCE FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P1269.	0.4	0
45	Incidental findings on brain imaging and blood tests: results from the first phase of Insight 46, a prospective observational substudy of the 1946 British birth cohort. BMJ Open, 2019, 9, e029502.	0.8	16
46	Learnings about the complexity of extracellular tau aid development of a bloodâ€based screen for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 487-496.	0.4	94
47	Title is missing!. , 2019, 14, e0224030.		O
48	Title is missing!. , 2019, 14, e0224030.		0
49	Title is missing!. , 2019, 14, e0224030.		О
50	Title is missing!. , 2019, 14, e0224030.		0
51	Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. BMC Research Notes, 2018, 11, 885.	0.6	37
52	O2â€05â€01: INFLUENCES OF BLOOD PRESSURE AND BLOOD PRESSURE TRAJECTORIES ON CEREBRAL PATHOLO AT AGE 70: RESULTS FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2018, 14, P626.	OGY 6.4	1
53	P1â€301: CERTAIN PLASMA Nâ€TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	О
54	Stability of bloodâ€based biomarkers of Alzheimer's disease over multiple freezeâ€thaw cycles. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 448-451.	1.2	49

#	Article	IF	CITATIONS
55	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	3.0	79
56	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, $2018,11,$	1.2	163
57	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimer's Research and Therapy, 2018, 10, 79.	3.0	43
58	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. Molecular Diagnosis and Therapy, 2017, 21, 13-22.	1.6	29
59	HERPES SIMPLEX TYPE 2 ASSOCIATED NEUROLOGICAL SYNDROMES. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.22-e4.	0.9	0
60	ELECTROLYTE IMBALANCE TRIGGERING RELAPSE OF INFLAMMATORY NEUROPATHY. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.120-e2.	0.9	0
61	Fortuitous findings. Journal of Infection, 2011, 63, 498-499.	1.7	1
62	Fortuitous vasculitis. Journal of Infection, 2011, 63, 504-505.	1.7	0